The price of VBI Vaccines Inc. (NASDAQ:VBIV) shares last traded on Wall Street fell -51.24% to $1.18.
Based on available information, 1 analysts follow VBI Vaccines Inc. (NASDAQ:VBIV). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $6.00, we find $6.00. Given the previous closing price of $2.42, this indicates a potential upside of 147.93 percent. VBIV stock price is now -56.84% away from the 50-day moving average and -90.28% away from the 200-day moving average. The market capitalization of the company currently stands at $9.72M.
Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
With the price target reduced from $5 to $2, Raymond James Downgraded its rating from Strong Buy to Outperform for VBI Vaccines Inc. (NASDAQ: VBIV).
In other news, PERCEPTIVE ADVISORS LLC, 10% Owner sold 4,251,563 shares of the company’s stock on Apr 06. The stock was sold for $467,672 at an average price of $0.11. Upon completion of the transaction, the 10% Owner now directly owns 41,440,729 shares in the company, valued at $48.9 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 05, 10% Owner PERCEPTIVE ADVISORS LLC sold 1,832,563 shares of the business’s stock. A total of $238,233 was realized by selling the stock at an average price of $0.13. This leaves the insider owning 45,691,816 shares of the company worth $53.92 million. A total of 0.52% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VBIV stock. A new stake in VBI Vaccines Inc. shares was purchased by VICTORY CAPITAL MANAGEMENT INC during the first quarter worth $1,000. In total, there are 138 active investors with 44.40% ownership of the company’s stock.
A candlestick chart of VBI Vaccines Inc. (NASDAQ: VBIV) showed a price of $1.4200 on Thursday morning. During the past 12 months, VBI Vaccines Inc. has had a low of $1.76 and a high of $40.50. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.80, and a quick ratio of 1.50. The fifty day moving average price for VBIV is $2.7000 and a two-hundred day moving average price translates $12.0289 for the stock.
The latest earnings results from VBI Vaccines Inc. (NASDAQ: VBIV) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$3.22, missing analysts’ expectations of -$1.25 by -1.97. This compares to -$2.47 EPS in the same period last year. The company reported revenue of $0.48 million for the quarter, compared to $0.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 284.92 percent. For the current quarter, analysts expect VBIV to generate $930k in revenue.
VBI Vaccines Inc.(VBIV) Company Profile
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
